LONDON (Reuters) – British biotech share listings last year generated their worst annual haul since 2012, an industry report published on Thursday found, mirroring a global downturn in initial public offerings (IPOs) across the sector. Only 28 million pounds ($34.7 million) – all in the first half of the year – was raised in IPOs by British biotech companies, the report from the UK BioIndustry Association (BIA) and insights company Clarivate showed. By way of comparison, total funds raised from UK IPOs amounted to roughly £1.3 billion in 2021, £244 million in 2020, £64 million in 2019 and £432…